Search
Position of EHA on Clinical Trials
The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.
Revision of the EU’s pharmaceutical legislation
Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.
Read morePress release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013
In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.
Read moreHighlights of Past EHA (HOPE) Cairo 2018
EHA returned to Cairo with the 3rd edition of the Highlights of Past EHA (HOPE). The meeting was organized in partnership with regional and national societies in the Middle East and North Africa.
Read moreHighlights of Past EHA (HOPE) Asia 2019
The 1st edition of the Highlights of Past EHA (HOPE) Asia 2019 took place in Kolkata, India. The meeting was organized in partnership with regional and national societies in Asia.
Read moreThe glamorous life of parenthood and medicine
The glamorous life of parenthood and medicine
By Ana Zelić Kerep, MD (YoungEHA Ambassador)
Is it possible to have it all – the career, the family, good health, and sanity? Is it possible to give all of yourself to work and still…
Current status of the Clinical Trials Regulation
HemAffairs Article #2 – June 2019
In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.
Position of EHA on Access to Medicines
There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.
Highlights of Past EHA (HOPE) Asia 2023
EHA joined forces with the Indian Society of Hematology & Blood Transfusion (ISHBT) to organize the 5th edition of the Highlights of Past EHA (HOPE) Asia 2023 meeting.
Read moreHighlights of Past EHA (HOPE) Asia 2020
EHA is returning to Sri Lanka for the 2nd edition of the Highlights of Past EHA (HOPE) Asia, organized with our hosting partner: the Sri Lanka College of Haematologists (SLCH).
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »